Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalaprilat Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalaprilat Anhydrous SCHEMBL4954583 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8149345 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL21046169 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8903287 | 0.99 | ACE (0.96) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8836365 | 0.99 | ACE (0.96) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL24327564 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL3090322 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL6106603 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL12737170 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL2406720 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11356 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4076652-B1 | A PHARMACEUTICALLY ACCEPTABLE SALT OF ATRASENTAN FOR USE IN A METHOD OF TREATING IGA NEPHROPATHY | CHINOOK THERAPEUTICS INC (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4525857-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-0363671-A2 | Use of ACE inhibitors against the formation of neo-intima after vascular infliction | F. HOFFMANN-LA ROCHE AG (CH) | 1990-04-18 | — | — | EP | claimed |
| US-4915954-A | Dosage form for delivering a drug at two different rates | ALZA CORPORATION (US) | 1990-04-10 | — | — | US | claimed |
| EP-0336950-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | claimed |
| WO-1989003691-A1 | POTENTIATION OF ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS | CIBA-GEIGY AG (CH) | 1989-05-05 | — | — | WO | claimed |
| EP-0278977-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS. | BUNDGAARD HANS (DK) | 1988-08-24 | — | — | EP | claimed |
| EP-0272177-A1 | Pharmaceutical composition containing diltiazem and an inhibitor of the enzyme-transforming angiotensin | SYNTHELABO (FR) | 1988-06-22 | — | — | EP | claimed |
| WO-1988001615-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS | BUNDGAARD HANS (DK) | 1988-03-10 | — | — | WO | claimed |
| EP-0241201-A2 | Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |